Market Research on Malignant Pleural Mesothelioma -Pipeline Review, H2 2016
Malignant Pleural Mesothelioma -Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Malignant Pleural Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.
To access full report with TOC, please visit Malignant Pleural Mesothelioma -Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Mesothelioma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Pleural Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Pleural Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 2 molecules, respectively.Malignant Pleural Mesothelioma.
Malignant Pleural Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malignant Pleural Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malignant Pleural Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology)
- The pipeline guide reviews pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malignant Pleural Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malignant Pleural Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Pleural Mesothelioma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Mesothelioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malignant Pleural Mesothelioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Advantagene, Inc. Amphera BV AnGes MG, Inc. ArQule, Inc. Bayer AG Biogen Inc Bionomics Limited Biotecnol Limited Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company CanBas Co., Ltd. Concordia International Corp Eli Lilly and Company EnGeneIC Ltd F. Hoffmann-La Roche Ltd. Genelux Corporation GlaxoSmithKline Plc Juno Therapeutics Inc. MedImmune LLC Merck & Co., Inc. Millennium Pharmaceuticals Inc MolMed S.p.A. Morphotek, Inc. Novartis AG Ono Pharmaceutical Co., Ltd. Oxford BioMedica Plc Pharma Mar, S.A. Polaris Pharmaceuticals, Inc. Sellas Inc Targovax ASA VasGene Therapeutics, Inc. Verastem, Inc. Virttu Biologics Limited Vyriad Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 07:17
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home